VEGF treatment promotes bone marrow-derived CXCR4⁺ mesenchymal stromal stem cell differentiation into vessel endothelial cells

QIMING LI¹, SHUDONG XIA¹, HANYUN FANG², JIANSHENG PAN², YINFENG JIA² and GANG DENG³

¹Department of Cardiology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, Zhejiang 322000; ²Department of Cardiology, The Second People’s Hospital of Yueqing, Yueqing, Zhejiang 325608; ³The Ningbo Central Blood Station, Ningbo, Zhejiang 315040, P.R. China

Received August 29, 2015; Accepted October 11, 2016

DOI: 10.3892/etm.2017.4019

Abstract. Stem/progenitor cells serve an important role in the process of blood vessel repair. However, the mechanism of vascular repair mediated by C-X-C chemokine receptor type 4-positive (CXCR4⁺) bone marrow-derived mesenchymal stem cells (BMSCs) following myocardial infarction remains unclear. The aim of the present study was to investigate the effects of vascular endothelial growth factor (VEGF) on vessel endothelial differentiation from BMSCs. CXCR4⁺ BMSCs were isolated from the femoral bone marrow of 2-month-old mice and the cells were treated with VEGF. Expression of endothelial cell markers and the functional properties were assessed by reverse transcription-quantitative polymerase chain reaction, flow cytometry and vascular formation analyses. The results indicated that the CXCR4⁺ BMSCs from femoral bone marrow cells expressed putative cell surface markers of mesenchymal stem cells. Treatment with VEGF induced platelet/endothelial cell adhesion molecule-1 (PECAM-1) and von Willebrand factor (vWF) expression at the transcriptional and translational levels, compared with untreated controls. Moreover, VEGF treatment induced CXCR4⁺ BMSCs to form hollow tube-like structures on Matrigel, suggesting that the differentiated endothelial cells had the functional properties of blood vessels. The results demonstrate that the CXCR4⁺ BMSCs were able to differentiate into vessel endothelial cells following VEGF treatment. For cell transplantation in vascular disease, it may be concluded that CXCR4⁺ BMSCs are a novel source of endothelial progenitor cells with high potential for application in vascular repair.

Introduction

Myocardial infarction is a leading cause of heart failure and mortality in developed countries. In recent years, bone marrow-derived mesenchymal stem cells (BMSCs) and endothelial progenitor cells (EPCs) have been reported to stimulate angiogenesis and collateral vessel formation in models of myocardial infarction and limb ischemia (1-3).

Williams and Hare reported that BMSCs and EPCs are able to integrate into vascular structures and differentiate into blood endothelial cells to participate in angiogenesis and tissue repair following ischemic injury (4). This may be favorable for physiological function and improve the patient survival rate (4), suggesting that BMSCs and EPCs serve an important role in angiogenesis (5).

Previous studies have found that the stem/progenitor cells can be recruited to areas of myocardial ischemia for vascular repair and this process may require chemokine and chemokine receptors (6,7). Chemokine receptor-expressing cells directly respond to chemokine stimulation, and are recruited to areas of injury or inflammation (8). The movement of chemotactic recruitment has been shown to be associated with the chemokine concentration (9). When myocardial infarction occurs, the transcription of stromal cell-derived factor (SDF-1) is significantly increased in the ischemic tissue. SDF-1 activates the expression of C-X-C chemokine receptor type 4-positive (CXCR4⁺) BMSCs to the myocardial infarction area, and their involvement in vessel repair and/or angiogenesis processes following myocardial infarction (10,11).

Studies have indicated that BMSCs expressing CXCR4 are able to promote myocardial repair when administered by cell transplantation following myocardial infarction (12,13). In the present study, the mechanisms by which CXCR4⁺ BMSCs differentiate into endothelial cells in vitro were investigated. The results may provide new insights providing a fundamental basis for the therapy of myocardial infarction.

Materials and methods

Antibodies and reagents. Anti-CXCR4 (cat no. sc-9046), anti-platelet/endothelial cell adhesion molecule-1 (PECAM-1;
cat. no. sc-52713) and anti-von Willebrand factor (vWF; cat. no. sc-8068) primary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). The secondary goat anti-mouse immunoglobulin (Ig) G (SA00007-1), goat anti-rabbit IgG (SA00007-2) and rabbit anti-goat IgG (SA00007-4) antibodies were purchased from Proteintech Group, Inc. (Chicago, IL, USA). Matrigel was purchased from Sigma-Aldrich (Merck Millipore, Darmstadt, Germany) while cluster of differentiation (CD) 117 (cat. no. 553355), CD54 (cat no. 561605), Flt-1, also known as vascular endothelial growth factor receptor 1 (VEGFR-1; cat. no. 561252) and CD107 (cat. no. 641581) antibodies were purchased from BD Pharmingen™, BD Biosciences (San Diego, CA, USA).

Isolation and culture of mouse CXCR4+ BMSCs. Six 2-month-old C57/BL6 female mice were obtained from Shanghai SLAC laboratory Animal Co., Ltd. (Shanghai, China) and allowed to acclimate for 1 week. Mice were housed at 20-22°C and 50-60% humidity with a 12:12-h light-dark cycle and ad libitum access to rodent chow and tap water. All procedures involving animals were approved by the Institutional Animal Care and Use Committee at the Zhejiang University (Zhejiang, China). BMSCs were isolated from the tibia and femur of the mice and 2x10⁵ cells/well were seeded in wells pretreated with 0.5% gelatin (cat. no. 9963; Sigma-Aldrich; Merck Millipore, Darmstadt, Germany). Cells were then incubated with Dulbecco's modified Eagle's medium (DMEM; cat. no. 11995065, Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (FBS; cat. no. 10082147, Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 5% CO₂, 37°C and 100% humidity. The culture medium was changed to remove suspended cells after 24 h. Following this, the medium was changed every 3 days. The cells were harvested by digestion when the BMSCs were passaged to the third generation. The cells were washed with PBS and then incubated with FBS containing CXCR4 antibody (10 µg/ml). Following incubation with anti-rabbit IgG magnetic beads (cat. no. 11203D, Thermo Fisher Scientific, Inc.), CXCR4+ cells were isolated using the DynaMag™-15 Magnet (cat. no. 12301D, Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions and the cell surface markers CD117, CD54, VEGFR-1 and CD107 were analyzed by flow cytometry using the BD FACS Calibur™ Operator (cat. no. 337662, BD Biosciences) (14). The purity of the CXCR4+ BMSCs was ≥95%.

Gene expression analysis. The sixth generation of CXCR4+ BMSCs (1x10⁶) were treated with 0, 10 or 20 ng/ml VEGF (cat. no. 19003, Proteintech Group, Inc.) for 24 h. There were three replicates per group. Total RNA was isolated from these cells using Trizol Reagent® (Invitrogen, Thermo Fisher Scientific, Inc.) and reverse transcribed using the SuperScript® III First-Strand Synthesis system for RT-PCR (cat. no. 18080-051, Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's instructions. The cDNA was amplified by quantitative PCR using the SYBR®-Green PCR Master mix (cat no. 4309155; Thermo Fisher Scientific, Inc.) using a CFX96 Touch Real-Time PCR Detection system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The primer sequences used were as follows: PECAM-1 forward, 5'-GAG AAGAGCAGCCGCATTCTT-3' and reverse, 5'-AACCTTCTTGCACCACTATGAGGTCTTCAATGC-3' and reverse, 5'-TTATTTGGGGCTCAGAA GGG-3'; GAPDH forward, 5'-CCAATGCCTTGCGCTA GAG-3' and reverse, 5'-CCTGGGAAAGGGTGTCCTGTA-3'. The cycling conditions were as follows: Initial denaturation at 95°C for 20 sec, 40 cycles amplification at 95°C for 3 sec and 60°C for 30 sec. All quantifications were normalized to GAPDH using the 2⁻ΔΔCT method (15).

Detection of PECAM-1 and vWF expression levels. CXCR4+ BMSCs were treated with 0, 10 or 20 ng/ml VEGF for 24 h, as described in the aforementioned paragraph. The cells were then collected and incubated with anti-PECAM-1 (1:100) and anti-vWF (1:100) antibodies for 1 h at room temperature, and subsequently incubated with the secondary goat anti-mouse IgG (1:150) and goat anti-rabbit IgG (1:200) antibodies for 1 h at room temperature. The isotype antibodies, normal rat IgG2a (1:150, cat. no. sc-3883) and normal goat IgG (1:150, cat. no. sc-3887), were purchased from Santa Cruz Biotechnology, Inc., and used as controls. The levels of PECAM-1 and vWF expression were analyzed by fluorescence-activated cell sorting (FACS) following a previously described protocol (14).

Capillary formation analysis. The procedure followed was as previously described (16). Firstly, 200 µl Matrigel (5 mg/ml) was added to 24-well plates, which were incubated at 37°C for 30 min for 1 h for polymerization. CXCR4+ BMSCs (400 µl, 3x10⁴ cells/ml) were then added to the Matrigel in the wells. Approximately 1.2x10⁴ cells were pre-treated with 20 ng/ml VEGF in the culture medium containing 1% FBS for 1 h. Following incubation of the cells for 3 and 6 h, angiogenesis phenomena were monitored under a light microscope and the length and size of tube-like structures were analyzed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

Statistical analysis. All experimental data are reported as the mean ± standard deviation. Statistical analyses were performed with a two-tailed unpaired t-test. P<0.05 was considered to indicate a statistically significant difference.

Results

Characterization of CXCR4+ BMSCs. CXCR4+ BMSCs isolated from BMSCs exhibited diverse morphology, for example, a round, spindle, long-spindle and spiral appearance (Fig. 1A). CXCR4+ BMSC-specific markers, namely CD117, CD54, Flt-1 (VEGFR-1) and CD107, were detected by FACS (Fig. 1B).

VEGF induces PECAM1 and vWF expression in CXCR4+ BMSCs. PECAM-1 is a glycoprotein, expressed on endothelial cells, which can induce cell–cell adhesion in a calcium-independent manner. PECAM-1 is considered as a specific marker of mature endothelial cells (17) and vWF is a glycoprotein subunit of endothelial cells, which promotes platelet cell adhesion (18). Treatment with 10 and 20 ng/ml VEGF significantly upregulated the expression level of PECAM-1 in CXCR4+ BMSCs (11.9±3.5 and 25.5±9.4-fold, respectively; P<0.05) compared with that of the control group, and the induction
occurred in a concentration-dependent manner (Fig. 2A). The vWF transcription level was also increased (12.5±4.2 and 18.4±8.6-fold, respectively; P<0.05) compared with that of the control group (Fig. 2B). These results indicate that VEGF treatment induced the expression of PECAM-1 and vWF in CXCR4⁺ BMSCs.

Protein levels in CXCR4⁺ BMSCs analyzed by FACS. FACS results showed that 10 and 20 ng/ml VEGF stimulation increased PECAM-1 levels in CXCR4⁺ BMSCs (8.32±2.54 and 17.86±3.86%) compared with those in the control group after 24 h (P<0.05; Fig. 3A). As shown in Fig. 3B, the vWF levels in CXCR4⁺ BMSCs were increased (10.45±2.58 and 25.56±7.98%; P<0.05) compared with those in the control group following stimulation with 10 and 20 ng/ml VEGF, respectively. These results indicate that VEGF stimulation is able to increase the levels of PECAM-1 and vWF in CXCR4⁺ BMSCs.
CXCR4+ BMSCs trigger the generation of vessel tube-like structures. Endothelial cells possess the ability to form vessel tube-like structures (19). CXCR4+ BMSCs were treated with VEGF for 1 h prior to being grown on Matrigel for 12 h, and then the morphology of the CXCR4+ BMSCs was observed under a light microscope. Some of the CXCR4+ BMSCs formed net- and tube-like structures (Fig. 4A). The tube length was increased to 1.54±0.24 and 1.87±0.34 mm/mm² for the CXCR4+ BMSCs stimulated with 10 and 20 ng/ml VEGF, respectively, which were higher than the tube length in the control group (0.46±0.14 mm/mm²). Compared with the control group, 20 ng/ml VEGF treatment increased the total tube length by up to 5-fold on average (P<0.05; Fig. 4B). These results indicate that CXCR4+ BMSCs promote the formation of capillary tube-like structures on Matrigel under VEGF stimulation.

Discussion

In the present study, it was identified that stem cell markers were expressed in CXCR4+ BMSCs and the mature endothelial cell markers PECAM-1 and vWF were induced following VEGF stimulation of the cells. PECAM-1, a glycoprotein of endothelial cells regarded as a specific marker of mature endothelial cells, is able to undergo intercellular adhesion in a non-calcium-dependent manner (17). VWF, a multimeric glycoprotein involved in endothelial cell-matrix interactions, is able to promote platelet adhesion (18). In the present study, it was found that VEGF stimulation triggered the formation of pseudopodia and tube-like structures by the CXCR4+ BMSCs on Matrigel. The formation of pseudopodia may be responsible for initiating the formation of vascular structures. These findings suggest that CXCR4+ BMSCs can differentiate into mature endothelial cells following stimulation with VEGF and could potentially be used as a source for cell transplantation. In addition, the observation that CXCR4+ BMSCs are capable of forming vessel-like structures, suggests that CXCR4+ BMSCs may act as endothelial progenitor cells and serve an important role in angiogenesis, with potential for use in the treatment of diseases of associated with vasculature, and vascular engineering and repair.

The goal of stem cell biology is to clinically utilize these cells for therapy. There is accumulating evidence that

Figure 3. VEGF-mediated alteration of PECAM-1 and vWF levels in CXCR4+ BMSCs. (A) PECAM-1 and (B) vWF protein levels were analyzed by fluorescence-activated cell sorting and quantified in the control and VEGF-stimulated CXCR4+ BMSCs. *P<0.05 vs. the control group. VEGF, vascular endothelial growth factor; PECAM-1, platelet/endothelial cell adhesion molecule-1; vWF, von Willebrand factor; CXCR4+ BMSCs, C-X-C chemokine receptor type 4-positive bone marrow-derived mesenchymal stem cells.
proxenitor cells have important roles in vascular development, hematopoiesis and reconstruction, bone marrow generation and blood circulation (20-22).

CXCR4+ mesenchymal stem cells (MSCs) possess the ability to differentiate into multiple types of cells, including osteocyte, adipose and endothelial cells (23,24). Previous studies reported that somatic cell and vascular endothelial progenitor cells are important for new vascular formation following vascular damage (25,26); for example, shortly after injury, endothelial progenitor cells derived from bone marrow have been found to promote the re-endothelialization of denuded arteries, and are able to repair the vasculature (27,28). Therefore, progenitor cells from bone marrow or circulating blood provide potential novel therapeutic techniques for certain diseases, such as the treatment of atherosclerosis and vascular stenosis, and the prevention of graft failure and cerebrovascular diseases (29). Stem/progenitor cell migration may be associated with the induction and effects of cytokines. Chemotactic factor SDF-1 interacts with its receptor CXCR4 and serves an important role in progenitor cell migration and differentiation (10,30,31). Previous studies have shown that tissue injury such as hypoxia and ischemia induces the production of a high amount of SDF-1 and activates CXCR4+ in endothelial progenitor cells (32,33), which is important for the generation of a SDF-1/CXCR4 interaction, cell mobilization and homing, and ischemia tissue repair. Shiba et al (34) and Seeger et al (35) reported that CXCR4+ MSCs enhanced therapeutic angiogenesis in cardiovascular disease and have increased potential for use in therapy.

In the present study, CXCR4+ BMSCs were isolated and it was identified that these cells express greater amounts of PECAM-1 and vWF proteins following VEGF stimulation. In addition, VEGF stimulation triggered the formation of tube-like structures from CXCR4+ BMSCs on Matrigel. These results indicate that CXCR4+ BMSCs have endothelial cell features and are able to differentiate into endothelial-like cells under appropriate induction conditions. Therefore, CXCR4 can be used as a selection marker for endothelial progenitor cells and MSCs, which is useful for obtaining highly pure endothelial progenitor cells. In conclusion, a method for the production of endothelial progenitor cells was established, in the present study and direct evidence of the differentiation and activation of BMSCs was provided, with potential use as a human stem cell-based targeted therapy.

Acknowledgements

This study was supported by a grant from Research Projects of Wenzhou Medical Science (grant no. 2014B63).
References

1. Turan RG, Bozdag TI, Turan CH, Ortak J, Akin I, Kische S, Schneider H, Rauchhaus M, Rehders TC, Kleinfeldt T, et al: Enhanced mobilization of the bone marrow-derived circulating progenitor cells by intracoronary freshly isolated bone marrow cells transplantation in patients with acute myocardial infarction. J Cell Mol Med 16: 852-864, 2012.

2. Fadini GP, Losordo D and Dimmeler S: Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res 110: 624-637, 2012.

3. Jiang Q, Ding S, Wu J, Liu X and Wu Z: Norepinephrine stimulates mobilization of endothelial progenitor cells after limb ischemia. PLoS One 9: e0117744, 2014.

4. Williams AR and Hare JM: Mesenchymal stem cells: Biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 109: 923-940, 2011.

5. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, et al: Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 360: 427-433, 2002.

6. Rennert CR, Sorkin M, Garg RK and Gurtner GC: Stem cell recruitment after injury: Lessons for regenerative medicine. Regen Med 7: 839-850, 2012.

7. Kanzler I, Tuchscheerer N, Steffens G, Simsekylizm S, Konsohalla S, Kroh A, Simons D, Asare Y, Schober A, Bucale R, et al: Differential roles of angiogenic chemokines in endothelial progenitor cell-induced angiogenesis. Basic Res Cardiol 108: 310, 2013.

8. Borsig L, Wolf MJ, Roblek M, Lorenzen A and Heik menwalder M: Inflammatory chemokines and metastasis-tracing the accessory. Oncogene 33: 3217-3224, 2014.

9. Roy I, Evans DB and Dwinell MB: Chemokines and chemokine receptors: Update on utility and challenges for the clinician. Surgery 155: 961-973, 2014.

10. Tang JM, Wang JN, Zhang L, Zheng F, Yang JY, Kong X, Guo LY, Chen L, Huang YZ, Wan Y and Chen SY: VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. Cardiovasc Res 91: 402-411, 2011.

11. Frederick JR, Fitzpatrick JR III, McCormick RC, Harris DA, Kim AY, Muenzer JR, Marotta N, Smith MJ, Cohen JE, Hiesinger W, et al: Stromal cell-derived factor-1alpha activation of tissue-engineered endothelial progenitor cell matrix enhances ventricular function after myocardial infarction by inducing neovascularization. Circulation 122 (Suppl 11): S107-S117, 2010.

12. Cheng Z, Ou L, Zhou X, Li F, Jia X, Zhang Y, Liu X, Li Y, Ward CA, Melo LG and Kong D: Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 126: 314-324, 2012.

13. Abbott JD, Huang Y, Liu D, Hickey R, Krause D and Giordano FJ: Stromal cell-derived factor-lalfa activation of tissue-engineered endothelial progenitor cell matrix enhances ventricular function after myocardial infarction by inducing neovascularization. Circulation 122 (Suppl 11): S107-S117, 2010.

14. Hoices KL, Otten G and Yokoyama WM: Flow cytometry analysis using the Becton Dickinson FACS Calibur. Curr Protoc Immunol Chapter 5: Unit 5.4, 2002.

15. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta Ct) method. Methods 25: 402-408, 2003.

16. Lee OH, Kim YM, Lee YM, Moon EJ, Lee DJ, Kim JH, Kim KW and Kwon YG: Sphinogmos 1-phosphate induces angiogenesis: Its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem Biophys Res Commun 264: 743-750, 1999.

17. Torszky M, Veynakova P, Richter S, Strobl H, Scheinecker C, Foedinger D and Riedl E: Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) and CD99 are critical in lymphatic transmigration of human dendritic cells. J Invest Dermatol 132: 1149-1157, 2012.

18. Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, Pastorino S, Yang M, Hoffman RM, Kesari S and Verma IM: Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci USA 108: 4274-4280, 2011.

19. Maniotis AJ, Folberg R, Hess A, Sefort EA, Gardner LM, Peer J, Trent JM, Melzter PS and Hendrix MJ: Vascular channel formation by human melanoma cells in vivo and in vitro: Vascularogenesis mimics. Am J Pathol 155: 739-752, 1999.

20. Minguell JJ, Erices A and Conej P: Mesenchymal stem cells. Exp Biol Med (Maywood) 226: 507-520, 2001.

21. Urbich C and Dimmeler S: Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res 95: 843-853, 2004.

22. Miyashima S, Sebastian J, Lee JY and Helariutta Y: Stem cell function during plant vascular development. EMBO J 32: 178-193, 2013.

23. Wei X, Yang X, Han ZP, Qu FF, Shao L and Shi YF: Mesenchymal stem cells: A new trend for cell therapy. Acta Pharmacol Sin 34: 747-754, 2013.

24. Fish KM: Mesenchymal stem cells drive cardiac stem cell Chemotaxis, proliferation and phenotype via CXCR4 and cKit signaling. Circ Res 119: 891-892, 2016.

25. Napoli C, Hayashi T, Cacciato P, Casamassimi A, Casini C, Al-Omran M and Ignarro LJ: Endothelial progenitor cells as therapeutic agents in the microcirculation: An update. Atherosclerosis 215: 9-22, 2011.

26. Xu Y, Arai H, Zhuge X, Sano H, Murayama T, Yoshimoto M, Heike T, Nakahata T, Nishikawa S, Kita T and Yokode M: Role of bone marrow-derived progenitor cells in cuff-induced vascular injury in mice. Arterioscler Thromb Vasc Biol 24: 477-482, 2004.

27. Gulati R, Jevremovic D, Peterson TE, Witt TA, Klepsle LS, Mueske CS, Lerman A, Vile RG and Simari RD: Autologous culture-modified mononuclear cells confer vascular protection after arterial injury. Circulation 108: 1520-1526, 2003.

28. Murphy MP, Lawson JH, Rapp BM, Dalsing MC, Klein J, Wilson MG, Huchins J and March KL: Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J Vasc Surg: 1565-1574.e1, 2011.

29. Wei L, Fraser JL, Lu ZY, Hu X and Yu SP: Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiol Dis 46: 635-645, 2012.

30. Hiesinger W, Perez-Aguilar JM, Atturi P, Marotta NA, Frederick JR, Fitzpatrick JR III, McCormick RC, Muenzer JR, Yang EC, Levid RT, et al: Computational protein design to reengineer stem cell-derived factor-10 generates an effective and translatable angiogenic polypeptide analog. Circulation 124 (Suppl 11): S18-S26, 2011.

31. Ghadhe SK, Muhlstedt S, Ozcelik C and Bader M: SDF-1α as a therapeutic stem cell homing factor in myocardial infarction. Pharmacol Ther 129: 97-108, 2011.

32. Dong F, Harvey J, Finan A, Weber K, Agarwal U and Penn MS: Myocardial CXCR4 expression is required for mesenchymal stem cell mediated repair following acute myocardial infarction. Circulation 126: 314-324, 2012.

33. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS and Giordano FJ: Stromal cell-derived factor-lalfa plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 110: 3300-3305, 2004.

34. Soda M, Liu F, Koda H, Murayama H, Morimoto H, Ise H, Nagasawa T and Ikeda U: Bone marrow CXCR4 induction by cultivation enhances therapeutic angiogenesis. Cardiovasc Res 81: 169-177, 2009.

35. Seeger FH, Rasper T, Koyanagi M, Fox H, Zeiher AM and Dimmeler S: CXCR4 expression determines functional activity of bone marrow-derived mononuclear cells for therapeutic neovascularization in acute ischemia. Arterioscler Thromb Vasc Biol 29: 1802-1809, 2009.